NO20060650L - Kinazolinderivater som angiogeneseinhibitorer - Google Patents

Kinazolinderivater som angiogeneseinhibitorer

Info

Publication number
NO20060650L
NO20060650L NO20060650A NO20060650A NO20060650L NO 20060650 L NO20060650 L NO 20060650L NO 20060650 A NO20060650 A NO 20060650A NO 20060650 A NO20060650 A NO 20060650A NO 20060650 L NO20060650 L NO 20060650L
Authority
NO
Norway
Prior art keywords
formula
compounds
aromatic
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20060650A
Other languages
English (en)
Inventor
Laurent Francois A Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060650L publication Critical patent/NO20060650L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I: hvor: ring C er en 8-, 9-, 10-, 12- eller 13-leddet bicyklisk eller tricyklisk gruppe, hvilken gruppe kan være mettet eller umettet, kan være aromatisk eller ikkearomatisk og som eventuelt kan inneholde 1-3 heteroatomer uavhengig valgt fra O, N og S; Z er -O-, -NH- eller -S-; n er 0, 1, 2, 3, 4 eller 5; m er 0, 1, 2 eller 3; og R1 og R2 er som definert her; og salter derav; anvendelse av dem ved fremstilling av et medikament for anvendelse for å produsere en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos varmblodige dyr; fremgangsmåter for fremstilling av slike forbindelser; farmasøytiske preparater inneholdende en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav og metoder for behandling av sykdomstilstander som involverer angiogenese ved administrering av en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav. Forbindelsene med formel (I) hemmer virkningene av VEGF, en egenskap verdifull ved behandling av flere sykdomstilstander omfattende kreft og revmatoid artritt.
NO20060650A 2003-08-06 2006-02-09 Kinazolinderivater som angiogeneseinhibitorer NO20060650L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318422.3A GB0318422D0 (en) 2003-08-06 2003-08-06 Chemical compounds
PCT/GB2004/003376 WO2005014582A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as angiogenesis inhibitors

Publications (1)

Publication Number Publication Date
NO20060650L true NO20060650L (no) 2006-04-24

Family

ID=27839732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060650A NO20060650L (no) 2003-08-06 2006-02-09 Kinazolinderivater som angiogeneseinhibitorer

Country Status (14)

Country Link
US (2) US7989460B2 (no)
EP (1) EP1658280A1 (no)
JP (1) JP4890249B2 (no)
KR (1) KR20060058705A (no)
CN (1) CN1863794B (no)
AU (1) AU2004263360A1 (no)
BR (1) BRPI0413284A (no)
CA (1) CA2534811A1 (no)
GB (1) GB0318422D0 (no)
IL (1) IL173484A0 (no)
MX (1) MXPA06001395A (no)
NO (1) NO20060650L (no)
WO (1) WO2005014582A1 (no)
ZA (1) ZA200601025B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
PE20021011A1 (es) * 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
UA81619C2 (ru) * 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
CN101072758B (zh) 2004-10-12 2013-07-31 阿斯利康(瑞典)有限公司 喹唑啉衍生物
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7851623B2 (en) * 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
BRPI0818244A2 (pt) * 2007-10-24 2015-06-16 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
US8211911B2 (en) * 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US9353123B2 (en) * 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
USD746538S1 (en) * 2014-02-03 2015-12-29 Nautilus Hyosung Inc. Automated teller machine
USD765340S1 (en) * 2014-03-24 2016-08-30 Nautilus Hyosung Inc. Automated teller machine
USD746539S1 (en) * 2014-03-24 2015-12-29 Nautilus Hyosung Inc. Automated teller machine
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
CN112996784B (zh) * 2018-09-18 2023-05-30 北京越之康泰生物医药科技有限公司 吲哚衍生物及其在医药上的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP2004505966A (ja) * 2000-08-09 2004-02-26 アストラゼネカ　アクチボラグ シンノリン化合物
JP2004511480A (ja) * 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
AU2002212436A1 (en) * 2000-10-25 2002-05-06 Astrazeneca Ab Quinazoline derivatives
US7501516B2 (en) * 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
AU2002347336A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
UA81619C2 (ru) * 2002-02-01 2008-01-25 Астразенека Аб Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2007071958A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of zd6474 and pemetrexed

Also Published As

Publication number Publication date
IL173484A0 (en) 2006-06-11
EP1658280A1 (en) 2006-05-24
ZA200601025B (en) 2007-05-30
WO2005014582A1 (en) 2005-02-17
KR20060058705A (ko) 2006-05-30
CA2534811A1 (en) 2005-02-17
US7989460B2 (en) 2011-08-02
JP4890249B2 (ja) 2012-03-07
JP2007501210A (ja) 2007-01-25
BRPI0413284A (pt) 2006-10-10
CN1863794A (zh) 2006-11-15
AU2004263360A1 (en) 2005-02-17
US20120046300A1 (en) 2012-02-23
GB0318422D0 (en) 2003-09-10
US20080058342A1 (en) 2008-03-06
CN1863794B (zh) 2012-04-25
MXPA06001395A (es) 2006-05-19

Similar Documents

Publication Publication Date Title
NO20060650L (no) Kinazolinderivater som angiogeneseinhibitorer
CN108235704B (zh) 抗细菌化合物
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP6963262B2 (ja) 新規抗癌剤
US9802951B2 (en) Biologically active taxane analogs and methods of treatment by oral administration
EP3027614A1 (de) Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
CN103896946B (zh) 用于预防及治疗多种自身免疫疾病的新化合物
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
NO20060641L (no) Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser
WO2018165614A1 (en) Bacterial efflux pump inhibitors
WO2019005841A1 (en) THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
IL207669A (en) Nitrogen compounds containing nitrogen active in chronic pain states
JP6155026B2 (ja) プロテインキナーゼ阻害のための新規化合物及びその治療的使用
CN115151541B (zh) 新型化合物及其用途
WO2020099929A1 (en) A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
AU2014258419A2 (en) Dicarboxylic acid compound
EP3454852A1 (en) Phosphotidylinositol 3-kinase inhibitors
KR20170037116A (ko) 플루오로기가 치환된 프탈라지논 유도체 및 그 제조방법
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
BR9910628A (pt) Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária
WO2019129114A1 (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
CN104487425B (zh) 治疗细菌性疾病的嘧啶衍生物
KR20080014017A (ko) (5ｚ)-5-(6-퀴녹살리닐메틸리덴)-2-[(2,6-디클로로페닐)아미노]-1,3-티아졸-4(5ｈ)-온
EP2406218A1 (en) Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application